HIS TWO SIBLINGS DIED FROM THE SAME RARE DISEASE — NOW, A GROUND-BREAKING TREATMENT IS GIVING THIS BABY A DIFFERENT FUTURE

For Lizzie, a mother living in a remote village in Alaska, the diagnosis of a rare genetic disease carried a devastating history. She had already lost two children to metachromatic leukodystrophy, a condition that gradually damages the nervous system. When her youngest son, Nicholas, was diagnosed with the same disease, the family faced the possibility of another heartbreaking loss.

But this time, there was a new option. Nicholas travelled with his parents across the country to Children’s Hospital of Philadelphia, where he received gene therapy at just six months old. His treatment offered a chance to intervene before the disease could take away abilities that many children develop naturally.

A Rare Disease That Can Steal a Child’s Abilities

Metachromatic leukodystrophy, known as MLD, is a rare inherited disorder that affects the protective covering surrounding nerve cells. As this covering deteriorates, communication between the brain and the rest of the body becomes increasingly difficult.

Children with the disease may initially appear healthy. Over time, however, they can lose skills such as walking, eating and speaking. The condition can progress rapidly, making early diagnosis especially important.

For Nicholas’s family, MLD was not an unfamiliar medical term. His older sister, Emily, also had the disorder, and an older son had died from it five years earlier. The family understood the devastating consequences that could follow a diagnosis.

Why Early Diagnosis Was So Important

Newborn screening helped identify Nicholas’s condition before the disease had progressed to the point where symptoms would become obvious. This early diagnosis made it possible for doctors to consider a treatment designed to intervene before significant neurological damage occurred.

According to his medical team, timing is critical. Gene therapy for MLD is most effective when it is administered before symptoms begin, because treatment cannot necessarily reverse damage that has already occurred.

For Lizzie, the opportunity to act early was especially significant. She had already experienced the loss of two children and now had a chance to pursue a different path for Nicholas.

A Journey Across Four Flights to Reach Treatment

Nicholas and his parents travelled from their remote Alaskan community to Philadelphia to reach the specialist team at Children’s Hospital of Philadelphia, commonly known as CHOP.

At six months old, Nicholas became the youngest MLD patient at the hospital to receive gene therapy. The treatment involved collecting some of his bone marrow stem cells, modifying them to introduce a working version of the relevant gene and returning the modified cells to his body after chemotherapy.

The process was complex and required specialist care. It also represented a major step forward for a family whose previous experience with MLD had ended in tragedy.

The Moment His Doctors Saw Him Walk

After treatment, Nicholas began demonstrating encouraging progress. His physician, Dr. Laura Adang, recalled a moment when he stood up and walked toward her.

She described seeing him talking, walking and doing the things she would expect a young toddler to do as one of the most remarkable moments of her career.

These milestones were especially meaningful because MLD can progressively take away abilities as the disease advances. Nicholas’s progress offered his family hope that early treatment might help preserve his development.

Back Home in Alaska With Hope for the Future

Nicholas has since returned to Alaska and was reported to be doing well. His progress continues to be monitored by his medical team, and his family celebrates each new milestone.

His story also highlights a major challenge in rare-disease care: early diagnosis depends on access to appropriate newborn screening. At the time of the report, MLD screening was available in only a limited number of US states.

Doctors at CHOP are working to help more children receive early diagnoses and access treatment before symptoms develop. The hospital reported that several additional children had received gene therapy after Nicholas.

A Different Possibility for Other Families

Nicholas’s treatment does not erase the family’s grief or guarantee the same outcome for every child with MLD. Gene therapy requires careful evaluation and follow-up, and the long-term effects must continue to be studied.

But his experience illustrates why early screening and advances in genetic medicine matter. When a rare disorder can be identified before symptoms appear, doctors may have an opportunity to intervene at a stage when treatment has the greatest chance of helping.

For Lizzie, every new milestone carries a meaning that few parents can fully understand. After losing two children to the same disease, watching Nicholas walk, talk and continue to grow offers a different kind of future — one her family once had little reason to expect.

Source: CBS News Philadelphia